Perspective Therapeutics (CATX) 10-Q 13 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 07, 2024
Cover [Abstract]
Entity Central Index Key	0000728387
Entity Registrant Name	PERSPECTIVE THERAPEUTICS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-33407
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1458152
Entity Address, Address Line One	2401 Elliott Avenue, Suite 320
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98121
City Area Code	206
Local Phone Number	676-0900
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	CATX
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		67,427,667

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents		$ 252,004	$ 9,238
Short-term investments		40,865	0
Accounts receivable, net of allowance for doubtful accounts: 2024 - $606; 2023 - $650		142	1,165
Prepaid expenses and other current assets		1,226	1,133
Current assets held for sale, discontinued operations		0	5,301
Total current assets		294,237	16,837
Noncurrent assets:
Property and equipment, net		14,747	5,576
Right-of-use asset, net		2,019	747
Restricted cash		182	182
Intangible assets, in-process research and development		50,000	50,000
Goodwill		24,062	24,062
Other assets, net		672	487
Total assets		385,919	97,891
Current liabilities:
Accounts payable and accrued expenses		6,127	6,909
Lease liability		720	46
Accrued personnel expenses		2,309	3,588
Note payable		54	49
Deferred Income (Note 3)		1,400	0
Current liabilities of discontinued operations		0	5,072
Total current liabilities		10,610	15,664
Noncurrent liabilities:
Lease liability		1,450	780
Note payable		1,651	1,676
Deferred Income (Note 3)		26,600	0
Deferred tax liability		4,592	4,592
Other noncurrent liabilities		19	0
Total liabilities		44,922	22,712
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible preferred stock; no shares issued and outstanding as of June 30, 2024 and December 31, 2023		0	0
Common stock, $0.001 par value; 750,000,000 shares authorized; 67,425,167 and 28,180,985 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	[1]	67	28
Additional paid-in capital	[1]	517,358	227,591
Accumulated deficit		(176,428)	(152,440)
Total stockholders' equity		340,997	75,179
Total liabilities and stockholders' equity		$ 385,919	$ 97,891
[1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) $ in Thousands	Jun. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Allowance for doubtful accounts | $	$ 606	$ 650
Preferred stock, par value | $ / shares	$ 0.001	$ 0.001
Preferred stock, shares authorized	7,000,000	7,000,000
Common stock, par value | $ / shares	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	67,425,167	28,180,985
Common stock, shares outstanding	67,425,167	28,180,985
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Grant revenue		$ 526	$ 588	$ 851	$ 821
Operating expenses:
Research and development		9,275	5,370	16,727	8,679
General and administrative		5,514	4,987	11,392	11,650
Change in estimate of asset retirement obligation (Note 4)		0	(15)	0	(15)
Loss on disposal of property and equipment		0	0	0	22
Total operating expenses		14,789	10,342	28,119	20,336
Operating loss		(14,263)	(9,754)	(27,268)	(19,515)
Non-operating income (expense):
Interest income		3,076	294	4,287	668
Interest and other expense		(23)	(26)	(52)	(44)
Equity in loss of affiliate		(4)	0	(6)	0
Total non-operating income (expense), net		3,049	268	4,229	624
Net loss from continuing operations		(11,214)	(9,486)	(23,039)	(18,891)
Net loss from discontinued operations		(429)	(1,620)	(890)	(3,086)
Loss recognized on classification as held for sale		(61)	0	(59)	0
Net loss before deferred income tax benefit		(11,704)	(11,106)	(23,988)	(21,977)
Deferred income tax benefit		0	0	0	10,500
Net loss		$ (11,704)	$ (11,106)	$ (23,988)	$ (11,477)
Basic and diluted loss per share:
Loss from continuing operations, Basic	[1]	$ (0.17)	$ (0.34)	$ (0.4)	$ (0.33)
Loss from continuing operations, Diluted	[1]	(0.17)	(0.34)	(0.4)	(0.33)
Loss from discontinued operations, Basic	[1]	(0.01)	(0.06)	(0.01)	(0.12)
Loss from discontinued operations, Diluted	[1]	(0.01)	(0.06)	(0.01)	(0.12)
Basic loss per share	[1]	(0.18)	(0.4)	(0.41)	(0.45)
Diluted loss per share	[1]	$ (0.18)	$ (0.4)	$ (0.41)	$ (0.45)
Weighted average shares used in computing net loss per share:
Basic	[1]	66,648	27,999	58,079	25,443
Diluted	[1]	66,648	27,999	58,079	25,443
[1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical)	Jun. 14, 2024
Income Statement [Abstract]
Reverse stock split	1-for-10 reverse stock split
Reverse stock split, ratio	0.1

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended		12 Months Ended
		Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss)		$ (11,704)	$ (12,284)	$ (11,106)	$ (371)	$ (23,988)	$ (11,477)
Adjustments to reconcile net loss to net cash provided by or used in operating activities:
Lease expense						71	(14)
Depreciation expense						916	425
Write-off of inventory associated with discontinued product						0	298
Loss on disposal of property and equipment						0	22
Amortization of other assets						12	20
Accretion of asset retirement obligation						0	17
Equity in loss of affiliate		4		0		6	0
Accrued interest on short-term investments						(360)	0
Change in allowance for doubtful accounts						(44)	0
Change in estimate of asset retirement obligation		0		(15)		0	(15)
Loss on divestiture						59	0
Share-based compensation						1,375	2,567
Deferred income tax benefit		0		0		0	(10,500)
Changes in operating assets and liabilities:
Accounts receivable						1,023	250
Inventory related to discontinued operations						11	144
Prepaid expenses and other current assets						(93)	(445)
Accounts payable and accrued expenses						(763)	442
Deferred Income	[1]					28,000	0
Accrued personnel expenses						(1,279)	471
Net cash provided by (used in) operating activities						4,946	(17,795)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment						(10,087)	(756)
Additions to other assets						0	(18)
Proceeds from maturity of short-term investments						38,225	22,764
Purchases of short-term investments						(78,730)	0
Net cash acquired in acquisition of Viewpoint						0	2,699
Net cash (used in) provided by investing activities						(50,592)	24,689
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of notes payable						(20)	(35)
Proceeds from sales of common stock, pursuant to exercise of warrants, net						123	0
Proceeds from sales of common stock, pursuant to exercise of option						254	532
Proceeds from Issuance of Common Stock and Prefunded Warrants Net	[1]					288,055	0
Issuance costs related to common stock issued in exchange for Viewpoint common stock						0	(65)
Net cash provided by financing activities						288,412	432
Net increase in cash, cash equivalents and restricted cash						242,766	7,326
Cash, cash equivalents and restricted cash beginning of period			$ 9,420		$ 21,175	9,420	21,175	$ 21,175
CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD		252,186		28,501		252,186	28,501	9,420
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:
Cash and cash equivalents		252,004		28,319		252,004	28,319	9,238
Restricted cash		182		182		182	182	182
Total cash, cash equivalents and restricted cash shown on the condensed consolidated statements of cash flows		$ 252,186		$ 28,501		252,186	28,501	$ 9,420
Supplemental schedule of noncash investing and financing activities:
Recognition of operating lease liability and right-of-use asset						1,497	0
Fair value of Viewpoint assets acquired including goodwill						0	85,885
13,654,507 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock						0	(54,618)
Assumption of Viewpoint stock options and warrants at fair value						0	(7,836)
Note receivable and accrued interest from Viewpoint forgiven						$ 0	$ (6,171)
[1] See Note 3, Investments and Agreements , for additional information.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	6 Months Ended
	Jun. 30, 2023 shares
Statement of Cash Flows [Abstract]
Shares issued in exchange for common stock (in shares)	136,545,072	[1]
[1] Amount for prior period presented has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands		Total	Common Stock [Member]		Additional Paid-in Capital [Member]		Accumulated Deficit [Member]	January 2024 Pre-funded Warrants [Member]	January 2024 Pre-funded Warrants [Member] Common Stock [Member]	[1]	January 2024 Pre-funded Warrants [Member] Additional Paid-in Capital [Member]	[1]	January 2024 Pre-funded Warrants [Member] Accumulated Deficit [Member]	May 2024 Pre-funded Warrants [Member]	May 2024 Pre-funded Warrants [Member] Common Stock [Member]	[1]	May 2024 Pre-funded Warrants [Member] Additional Paid-in Capital [Member]	[1]	May 2024 Pre-funded Warrants [Member] Accumulated Deficit [Member]	Public Offering [Member]	Public Offering [Member] Common Stock [Member]		Public Offering [Member] Additional Paid-in Capital [Member]	[1]	Public Offering [Member] Accumulated Deficit [Member]	Lantheus Investment Agreement [Member]	Lantheus Investment Agreement [Member] Common Stock [Member]		Lantheus Investment Agreement [Member] Additional Paid-in Capital [Member]	[1]	Lantheus Investment Agreement [Member] Accumulated Deficit [Member]	March 2024 Investment Agreement [Member]	March 2024 Investment Agreement [Member] Common Stock [Member]		March 2024 Investment Agreement [Member] Additional Paid-in Capital [Member]	[1]	March 2024 Investment Agreement [Member] Accumulated Deficit [Member]	A T M Agreement [Member]	A T M Agreement [Member] Common Stock [Member]		A T M Agreement [Member] Additional Paid-in Capital [Member]	[1]	A T M Agreement [Member] Accumulated Deficit [Member]	Registered Offering [Member]	Registered Offering [Member] Common Stock [Member]		Registered Offering [Member] Additional Paid-in Capital [Member]	[1]	Registered Offering [Member] Accumulated Deficit [Member]
Balances (in shares) at Dec. 31, 2022	[1]		14,211,276
Balances at Dec. 31, 2022		$ 54,642	$ 14	[1]	$ 160,560	[1]	$ (105,932)
Issuance of common stock in exchange for Viewpoint common stock, net of issuance costs (in shares)	[1]		13,654,507
Issuance of common stock in exchange for Viewpoint common stock, net of issuance costs		54,553	$ 14	[1]	54,539	[1]	0
Assumption of Viewpoint stock options and warrants at fair value		7,836	0	[1]	7,836	[1]	0
Share-based compensation		1,368	0	[1]	1,368	[1]	0
Net loss		(371)	$ 0	[1]	0	[1]	(371)
Balances (in shares) at Mar. 31, 2023	[1]		27,865,783
Balances at Mar. 31, 2023		118,028	$ 28	[1]	224,303	[1]	(106,303)
Balances (in shares) at Dec. 31, 2022	[1]		14,211,276
Balances at Dec. 31, 2022		54,642	$ 14	[1]	160,560	[1]	(105,932)
Net loss		(11,477)
Balances (in shares) at Jun. 30, 2023	[1]		28,047,941
Balances at Jun. 30, 2023		108,653	$ 28	[1]	226,034	[1]	(117,409)
Balances (in shares) at Mar. 31, 2023	[1]		27,865,783
Balances at Mar. 31, 2023		118,028	$ 28	[1]	224,303	[1]	(106,303)
Issuance of common stock pursuant to exercise options (in shares)	[1]		182,158
Issuance of common stock pursuant to exercise of options		532	$ 0	[1]	532	[1]	0
Share-based compensation		1,199	0	[1]	1,199	[1]	0
Net loss		(11,106)	$ 0	[1]	0	[1]	(11,106)
Balances (in shares) at Jun. 30, 2023	[1]		28,047,941
Balances at Jun. 30, 2023		108,653	$ 28	[1]	226,034	[1]	(117,409)
Balances (in shares) at Dec. 31, 2023	[1]		28,180,985
Balances at Dec. 31, 2023		75,179	$ 28	[1]	227,591	[1]	(152,440)
Issuance of common stock, net (in shares)	[1],[2]																				15,639,954						5,634,235						9,200,998
Issuance of common stock, net	[2]																			$ 53,141	$ 16	[1]	$ 53,125		$ 0	$ 20,846	$ 6	[1]	$ 20,840		$ 0	$ 82,019	$ 9	[1]	$ 82,010		$ 0
Issuance of Pre-funded Warrants, net	[2]							$ 10,208	$ 0		$ 10,208		$ 0
Issuance of common stock pursuant to exercise options (in shares)	[1]		35,424
Issuance of common stock pursuant to exercise of options		126	$ 0	[1]	126	[1]	0
Share-based compensation		656	0	[1]	656	[1]	0
Net loss		(12,284)	$ 0	[1]	0	[1]	(12,284)
Balances (in shares) at Mar. 31, 2024	[1]		58,691,596
Balances at Mar. 31, 2024		229,891	$ 59	[1]	394,556	[1]	(164,724)
Balances (in shares) at Dec. 31, 2023	[1]		28,180,985
Balances at Dec. 31, 2023		75,179	$ 28	[1]	227,591	[1]	(152,440)
Net loss		(23,988)
Balances (in shares) at Jun. 30, 2024	[1]		67,425,167
Balances at Jun. 30, 2024		340,997	$ 67	[1]	517,358	[1]	(176,428)
Balances (in shares) at Mar. 31, 2024	[1]		58,691,596
Balances at Mar. 31, 2024		229,891	$ 59	[1]	394,556	[1]	(164,724)
Issuance of common stock, net (in shares)	[1],[2]																																						3,535,246						5,151,588
Issuance of common stock, net	[2]																																					$ 47,933	$ 3	[1]	$ 47,930		$ 0	$ 71,868	$ 5	[1]	$ 71,863		$ 0
Issuance of Pre-funded Warrants, net	[2]													$ 2,040	$ 0		$ 2,040		$ 0
Issuance of common stock pursuant to exercise options (in shares)	[1]		24,450
Issuance of common stock pursuant to exercise of options		128	$ 0	[1]	128	[1]	0
Issuance of stock pursuant to exercise of common stock warrants	[1]	123			123
Issuance of common stock pursuant to exercise of warrants (in shares)	[1]		22,401
Share-based compensation		719	$ 0	[1]	719	[1]
Cancellation of fractional shares due to the 1-for-10 reverse stock split		(1)	$ 0	[1]	(1)	[1]	0
Cancellation of fractional shares due to the 1-for-10 reverse stock split (in shares)	[1]		(114)
Net loss		(11,704)	$ 0	[1]	0	[1]	(11,704)
Balances (in shares) at Jun. 30, 2024	[1]		67,425,167
Balances at Jun. 30, 2024		$ 340,997	$ 67	[1]	$ 517,358	[1]	$ (176,428)
[1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for- 10 reverse stock split effected on June 14, 2024. See Note 1 for details. See Note 3, Investments and Agreements , for additional information.

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)	Jun. 14, 2024
Statement of Stockholders' Equity [Abstract]
Reverse stock split	1-for-10 reverse stock split
Reverse stock split, ratio	0.1

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (11,704)	$ (12,284)	$ (11,106)	$ (371)	$ (23,988)	$ (11,477)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		ITEM 5 – O THER INFORMATION Rule 10b5-1 Trading Arrangements During the three months ended June 30, 2024 , none of our directors or executive officers adopted , modified or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. Basis of Presentation and Summary of Significant Accounting Policies Perspective Therapeutics, Inc. is developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. The accompanying unaudited condensed consolidated financial statements are those of Perspective Therapeutics, Inc., and its wholly owned subsidiaries, referred to herein as “Perspective Therapeutics” or the “Company.” All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair statement of the condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes as set forth in the Company’s Annual Report on Form 10-K for the period ended December 31, 2023 filed with the SEC on March 28, 2024 (2023 Form 10-K). The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures are adequate for the information not to be misleading. The unaudited condensed consolidated financial statements reflect, in management’s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s financial position, results of operations and cash flows for the interim periods, but are not necessarily indicative of the results expected for the full fiscal year or any other period. The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2024 will be 0 %. Merger On February 3, 2023, the Company completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company, with Viewpoint Molecular Targeting, Inc. (Viewpoint) (such transaction being the Merger). Pursuant to the Merger, the Company issued 13,654,507 shares of its common stock, par value $ 0.001 per share (Common Stock), representing approximately 49 % of its fully diluted outstanding capital stock as of the close of the Merger. Viewpoint is an alpha-particle radiopharmaceutical company in the alpha-emitter market developing oncology therapeutics and complementary imaging agents. For additional information, see Note 14, Merger , in this Form 10-Q. Discontinued Operations On April 12, 2024, the Company completed the sale of its Cesium-131 brachytherapy business and substantially all of the assets of Isoray Medical, Inc. (Isoray), a wholly owned subsidiary of Perspective Therapeutics , to GT Medical Technologies, Inc., a Delaware corporation (GT Medical) (such transaction being the GT Medical Closing). Pursuant to the GT Medical Closing, GT Medical issued to Isoray 279,516 shares of GT Medical’s common stock, par value $ 0.0001 per share, representing 0.5 % of GT Medical’s issued and outstanding capital stock on a fully diluted basis as of the closing. Accordingly, the financial information and operating results of the Cesium-131 brachytherapy business have been presented as discontinued operations in the condensed consolidated financial statements for all periods presented. Unless otherwise noted, discussion within these notes to the condensed consolidated financial statements relates to continuing operations. For additional information, see Note 4, Discontinued Operations , in this Form 10-Q. Reverse Stock Split On June 14, 2024, the Company effected a 1-for-10 reverse stock split (Reverse Split) of the Company’s issued and outstanding shares of Common Stock, and the Common Stock began trading on a split-adjusted basis on June 17, 2024. The Reverse Split did not reduce the total number of authorized shares of Common Stock or the Company’s preferred stock (Preferred Stock), or change the par values of the Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholder’s ownership percentage of the shares of Common Stock (except to the extent that the Reverse Split resulted in some of the stockholders receiving cash in lieu of fractional shares). All outstanding options and warrants entitling their holders to purchase shares of Common Stock were adjusted as a result of the Reverse Split, in accordance with the terms of each such security. In addition, the number of shares reserved for future issuance pursuant to the Company’s equity incentive plans was also adjusted accordingly. As a result, all historical per share data, number of shares issued and outstanding, and outstanding options and warrants for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively in this Form 10-Q, where applicable, to reflect the Reverse Split. Liquidity The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has had a history of operating losses and an absence of significant recurring cash inflows from revenue. At June 30, 2024, the Company had cash, cash equivalents and short-term investments of $ 292.9 million and total accumulated deficit of $ 176.4 million. The Company has historically financed its operations primarily through selling equity. The Company believes that its $ 292.9 million of cash, cash equivalents and short-term investments as of June 30, 2024 will enable it to fund its current planned operations into mid-2026, though it may raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and/or government funding and grants. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The operating plan may change as a result of many factors currently unknown to management, and there can be no assurance that the current operating plan will be achieved in the timeframe anticipated by management or at all, and the Company may need to seek additional funds sooner than anticipated. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from potential unknown factors. Reclassifications In addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows. Significant Accounting Policies The Company’s significant accounting policies and recent accounting pronouncements are described in Note 2, Summary of Significant Accounting Policies , to the consolidated financial statements in Item 8 of the 2023 Form 10-K. There have been no changes to the Company’s significant accounting policies, and the Company has not adopted any significant accounting policies during the six months ended June 30, 2024 .

Note 2 - Loss Per Share

Note 2 - Loss Per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Loss Per Share	2. Loss per Share Basic and diluted loss per share is calculated by dividing net loss by the weighted average number of shares of Common Stock outstanding and does not include the impact of any potentially dilutive common stock equivalents. In January 2024 and May 2024, the Company issued pre-funded warrants in connection with the Public Offering (as defined below) and the Registered Offering (as defined below), respectively (see Note 3, Investments and Agreements , in this Form 10-Q). As the pre-funded warrants’ exercise price is nominal and there are no conditions that must be satisfied prior to their exercise, the pre-funded warrants are included in the calculation of the basic and diluted earnings per share as of June 30, 2024. At each of June 30, 2024 and 2023, the calculation of diluted weighted average shares did not include common stock warrants or options that were potentially convertible into Common Stock as those would be antidilutive due to the Company’s net loss position. Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands): June 30, 2024 June 30, 2023 Common stock warrants 416 603 Common stock options 6,934 4,487 Total potential dilutive securities 7,350 5,090 Effective upon the closing of the Merger with Viewpoint on February 3, 2023, the Company assumed 338,709 warrants to purchase shares of Common Stock with an exercise price of $ 2.70 per share and 2,426,342 options to purchase shares of Common Stock with exercise prices ranging from $ 1.30 to $ 3.00 per share.

Note 3 - Investments and Agreem

Note 3 - Investments and Agreements	6 Months Ended
	Jun. 30, 2024
Investment Agreements [Abstract]
Investments and Agreements	3. Investments and Agreements May 2024 Registered Offering On May 24, 2024, the Company entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters named therein, in connection with its previously announced underwritten offering (Registered Offering) of 5,151,588 shares (Registered Offering Shares) of Common Stock and, in lieu of Registered Offering Shares to certain investors, pre-funded warrants (May 2024 Pre-funded Warrants) to purchase 146,425 shares of Common Stock. The price to the investors for the Registered Offering Shares was $ 15.10 per Registered Offering Share, and the price to the investors for the May 2024 Pre-funded Warrants was $ 15.09 per May 2024 Pre-funded Warrant, which represents the per share price for the Registered Offering Shares less the $ 0.01 per share exercise price for each such May 2024 Pre-funded Warrant. The Registered Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Registered Offering and B. Riley Securities, Inc. acted as a co-manager for the Registered Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Registered Offering. The gross proceeds to the Company from the Registered Offering were approximately $ 80 million, before underwriting discounts and commissions and estimated expenses of the Registered Offering. The Company intends to use the net proceeds from the Registered Offering for: (i) the continued clinical development of VMT-α-NET, VMT-01/02 and PSV359; (ii) the continued development of PSV40X and additional preclinical product candidates as well as a broader development platform; and (iii) the build out, operation and expansion of manufacturing facilities, as well as for working capital and other general corporate purposes. A portion of the net proceeds may also be used to acquire, license or invest in complementary products, technologies, intellectual property or businesses, although the Company has no present commitments or agreements to do so. The Registered Offering was made pursuant to the Company’s automatic shelf registration statement on Form S-3 (File No. 333-279692) (the May 2024 Registration Statement), which became effective upon filing with the SEC on May 24, 2024, a related base prospectus, free writing prospectus and prospectus supplement each dated May 24, 2024. The May 2024 Pre-funded Warrants became exercisable subsequent to the filing and effectiveness of an amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 14, 2024. The exercise price and the number of shares of Common Stock issuable upon exercise of each May 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Company’s stockholders. The May 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of May 2024 Pre-funded Warrants may not exercise such May 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would be more than 4.99 % or 9.99 %, as elected by such holder, of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the May 2024 Pre-funded Warrants. A holder of May 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99 % by providing at least 61 days’ prior notice to the Company. March 2024 Private Placement with Institutional Investors On March 4, 2024, the Company entered into an investment agreement (the March 2024 Investment Agreement) with certain accredited institutional investors (Institutional Investors) pursuant to which the Company agreed to issue and sell, in a private placement (the March 2024 Private Placement), 9,200,998 shares of Common Stock, for a purchase price of $ 9.50 per share, representing the closing price of the Common Stock on March 1, 2024. The closing of the March 2024 Private Placement occurred on March 6, 2024. The gross proceeds to the Company from the March 2024 Private Placement were approximately $ 87.4 million, before deducting fees payable to the Placement Agents (as defined below) and other estimated transaction expenses. The Company intends to use the net proceeds from the March 2024 Private Placement for general corporate and working capital purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, capital expenditures, acquisitions of new technologies, products or businesses and investments. The March 2024 Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the Placement Agency Agreement), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the Placement Agents). Per the Placement Agency Agreement, the Company agreed to: (i) pay the Placement Agents a cash fee equal to 5.85 % of the gross proceeds received by the Company from the sale of the shares; and (ii) reimburse the Placement Agents for certain fees and expenses. Lantheus Agreements Investment Agreement On January 8, 2024, the Company entered into an investment agreement (the Lantheus Investment Agreement) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company and wholly owned subsidiary of Lantheus Holdings, Inc. (Lantheus), pursuant to which the Company agreed to sell and issue to Lantheus in a private placement transaction certain shares (the Lantheus Shares) of Common Stock. The closing of the purchase and sale of the Lantheus Shares to Lantheus by the Company (the Lantheus Closing) was subject to the Company raising at least $ 50.0 million of gross proceeds (excluding Lantheus’ investment) in a qualifying third-party financing transaction, which occurred on January 22, 2024. The number of Lantheus Shares sold was 5,634,235 , representing 19.99 % of the outstanding shares of Common Stock as of January 8, 2024. Pursuant to the Lantheus Investment Agreement, the Company agreed to cooperate in good faith to negotiate and enter into a registration rights agreement with Lantheus, obligating the Company to file a registration statement on Form S-3 with the SEC to register for resale the Lantheus Shares issued at the Lantheus Closing. The Company filed such Form S-3 on March 29, 2024, and the SEC declared it effective on April 9, 2024 (File No. 333-278362). The Lantheus Investment Agreement also contains agreements of the Company and Lantheus whereby Lantheus is provided certain board observer and information rights of the Company, as well as standstill provisions prohibiting Lantheus from taking certain actions for a specified period of time, subject to certain exceptions. The Lantheus Investment Agreement also provides Lantheus with certain pro rata participation rights to maintain its ownership position in the Company in the event that the Company makes any public or non-public offering of any equity or voting interests in the Company or any securities that are convertible or exchangeable into (or exercisable for) equity or voting interests in the Company, subject to certain exceptions. Pursuant to the Lantheus Investment Agreement, the Company is required to notify Lantheus within 10 business days of the end of a fiscal quarter in which the Company issued shares of Common Stock pursuant to that certain At Market Issuance Sales Agreement among the Company, Oppenheimer & Co. Inc., B. Riley Securities, Inc., and JonesTrading Institutional Services LLC dated November 17, 2023 (the ATM Agreement), of (i) the number of shares of Common Stock issued during such fiscal quarter pursuant to the ATM Agreement and (ii) the average price per share received by the Company before commissions (the ATM Average Price). Upon receipt of such notice, Lantheus may elect, at its option, to purchase all or a portion of its Pro Rata Portion (as defined in the Lantheus Investment Agreement) of such shares at an aggregate price equal to the number of shares purchased multiplied by the ATM Average Price for such quarter (the ATM Participation Right). Pursuant to the Lantheus Investment Agreement, Lantheus may not exercise the ATM Participation Right more than two times per calendar year. Asset Purchase Agreement On January 8, 2024, the Company entered into an Asset Purchase Agreement (the Progenics APA) with Progenics Pharmaceuticals, Inc., a Delaware corporation (Progenics) and affiliate of Lantheus, pursuant to which the Company acquired certain assets and the associated lease of Progenics’ radiopharmaceutical manufacturing facility in Somerset, New Jersey for a purchase price of $ 8.0 million in cash. The transactions contemplated by the Progenics APA closed on March 1, 2024. Option Agreement On January 8, 2024, the Company entered into an option agreement (the Option Agreement) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide, royalty- and milestone-bearing right and license to [ 212 Pb]VMT-α-NET, the Company’s clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors. If good-faith negotiations fail, Lantheus has a one-year right to reenter negotiations if a third party offers to purchase or license the [ 212 Pb]VMT-α-NET program. Additionally, Lantheus has a right to co-fund the Investigational New Drug (IND) application, enabling studies for early-stage therapeutic candidates targeting prostate-specific membrane antigen and gastrin-releasing peptide receptor and, prior to IND filing, a right to negotiate for an exclusive license to such candidates. In consideration of the rights granted by the Company to Lantheus pursuant to the Option Agreement, Lantheus paid to the Company a one-time payment of $ 28.0 million, subject to certain withholding provisions associated with the closing of the Progenics APA. Under the terms of the Option Agreement, Lantheus also has a right of first offer and last look protections for any third-party merger and acquisition transactions involving the Company for a 12-month period beginning on January 8, 2024. The Company determined that the Option Agreement should be accounted for as a research and development arrangement in accordance with ASC 730-20, Research and Development Arrangements , as Lantheus held approximately 19.9 % of the Company’s outstanding Common Stock at March 31, 2024. The Option Agreement contains no repayment provisions, does not create any obligation to enter into any license, transfer or sale agreements with Lantheus, and does not restrict the use of the funds in any way. Accordingly, the balance sheet reports current and long-term liabilities related to these options under the caption, “Deferred Income.” The values for each distinct option within the Option Agreement were determined by estimating the fair value of each distinct option by a third-party valuation firm and the liabilities will be recognized as income in the condensed consolidated statement of operations as the various options expire. January 2024 Public Offering On January 17, 2024, the Company entered into an underwriting agreement (Underwriting Agreement) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the Underwriters), in connection with its previously announced underwritten public offering (Public Offering) of 13,207,521 shares (Public Shares) of Common Stock and, in lieu of Public Shares to certain investors, pre-funded warrants (Jan. 2024 Pre-funded Warrants) to purchase 3,008,694 shares of Common Stock. The price to the public for the Public Shares was $ 3.70 per Public Share, and the price to the public for the Jan. 2024 Pre-funded Warrants was $ 3.69 per Jan. 2024 Pre-funded Warrant, which represents the per share price for the Public Shares less the $ 0.01 per share exercise price for each such Jan. 2024 Pre-funded Warrant. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,432,432 shares of Common Stock at the same price per share as the Public Shares, which was fully exercised by the Underwriters on January 18, 2024. The Public Offering closed on January 22, 2024. The gross proceeds to the Company from the Public Offering were approximately $ 69.0 million, before underwriting discounts and commissions and estimated expenses of the Public Offering. The Company intends to use the net proceeds from the Public Offering for general corporate purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, working capital, capital expenditures, acquisitions of new technologies, products or businesses and investments. The Public Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-275638), declared effective by the SEC on December 14, 2023, a base prospectus dated December 14, 2023, and the related prospectus supplement dated January 17, 2024. The Jan. 2024 Pre-funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of each Jan. 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Company’s stockholders. The Jan. 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Jan. 2024 Pre-funded Warrants may not exercise such Jan. 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would beneficially own more than 4.99 % of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Jan. 2024 Pre-funded Warrants. A holder of Jan. 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99 % by providing at least 61 days’ prior notice to the Company. ATM Agreement Pursuant to the ATM Agreement, the Company has established an “at-the-market” equity program under which it may offer and sell shares of its Common Stock, from time to time. On November 17, 2023, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-275638) and accompanying base prospectus, declared effective by the SEC on December 14, 2023, for the offer and sale of up to $ 200 million of its securities (December 2023 Registration Statement). Also on November 17, 2023, the Company filed a prospectus supplement with the SEC in connection with the offering of up to $ 50 million of shares of its Common Stock pursuant to the ATM Agreement under the December 2023 Registration Statement. In December 2023, the Company sold 123,882 shares under the ATM Agreement at an average price of approximately $ 3.03 per common share for gross proceeds of approximately $ 0.4 million. On April 11, 2024, the Company sold 3,535,246 shares of its Common Stock under the ATM Agreement at an average price of approximately $ 14.00 per common share, resulting in gross proceeds of approximately $ 49.5 million. On May 25, 2024, the Company terminated the offering of securities pursuant to the December 2023 Registration Statement in connection with the filing and effectiveness of the May 2024 Registration Statement. For additional information related to the various agreements discussed above, see Note 20, Subsequent Events , in the Company’s 2023 Form 10-K.

Note 4 - Discontinued Operation

Note 4 - Discontinued Operations	6 Months Ended
	Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	4. Discontinued Operations The GT Medical Closing occurred on April 12, 2024 (GT Medical Closing Date). Previously, the Company announced that on December 7, 2023, Isoray entered into an Asset Purchase Agreement (GT Medical APA) by and among Isoray, the Company, and GT Medical pursuant to which Isoray would sell to GT Medical, and GT Medical would purchase from Isoray, all of Isoray’s right, title and interest in and to substantially all of the assets of Isoray related to Isoray’s commercial Cesium-131 business (the Business) including equipment, certain contracts, inventory and intellectual property. Subject to limited exceptions set forth in the GT Medical APA, GT Medical did not assume the liabilities of Isoray. Pursuant to the terms of, and subject to the conditions specified in, the GT Medical APA, at the GT Medical Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medical’s common stock, par value $ 0.0001 per share, representing 0.5 % of GT Medical’s issued and outstanding capital stock on a fully diluted basis as of the GT Medical Closing Date and (ii) Isoray has the right to receive, and GT Medical is obligated to pay, certain cash royalty payments during each of the first four years beginning upon the GT Medical Closing Date (each such year, a Measurement Period), as summarized below: • with respect to GT Medical’s net sales of Cesium-131 brachytherapy seeds for cases that do not utilize GT Medical’s GammaTile Therapy: (a) if such net sales for a Measurement Period are $10 million or less, 3.0 % of such net sales; (b) if such net sales for a Measurement Period are greater than $10 million and less than $15 million, 4.0 % of such net sales; and (c) if such net sales for a Measurement Period are $15 million or more, 5.0 % of such net sales; and • with respect to GT Medical’s net sales of GT Medical’s GammaTile Therapy utilizing Cesium-131 brachytherapy seeds: 0.5 % of such net sales for a Measurement Period. In accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations , the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified. June 30, 2024 December 31, 2023 (in thousands) Assets held for sale of discontinued operations, current Inventory $ - $ 3,148 Prepaid expenses and other current assets - 169 Property and equipment, net - 1,263 Right-of-use asset, net - 676 Other assets, net - 45 Total current assets held for sale of discontinued operations $ - $ 5,301 Liabilities held for sale of discontinued operations, current Lease liability $ - $ 677 Asset retirement obligation - 225 Loss recognized on classification as held for sale - 4,170 Total current liabilities of discontinued operations $ - $ 5,072 The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Sales, net $ 205 $ 1,500 $ 2,178 $ 3,330 Cost of sales 162 1,840 1,564 3,416 Gross profit 43 ( 340 ) 614 ( 86 ) Operating expenses: Research and development 21 283 69 831 Sales and marketing 138 911 941 1,723 General and administrative 313 86 494 446 Total operating expenses 472 1,280 1,504 3,000 Total loss from discontinued operations $ ( 429 ) $ ( 1,620 ) $ ( 890 ) $ ( 3,086 ) The Company determined the loss recognized on classification as held for sale by identifying the assets and liabilities that are included in the GT Medical APA and are included in the table above. Additionally, the loss recognized on classification as held for sale was determined using the estimated fair value of the GT Medical stock of $ 0.2 million received less the carrying value of the net assets sold. The fair value of the stock received was determined based on information provided to the Company by GT Medical from a current valuation study that was prepared for them. Excluded from the calculation of the loss are contingent royalties that could be received from future sales. Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands): Six Months Ended June 30, 2024 2023 Depreciation $ - $ 111 Amortization - 18 Write-off of inventory associated with discontinued product - 298 Share-based compensation 166 535 Additions to property and equipment - 186 For the three and six months ended June 30, 2024 and 2023 , there was no provision (benefit) for income taxes recorded related to the discontinued operations. Additionally, the Company is in a loss position and has recorded a full valuation allowance for the deferred tax assets associated with the discontinued operations.

Note 5 - Property and Equipment

Note 5 - Property and Equipment	6 Months Ended
	Jun. 30, 2024
Notes To Financial Statements [Abstract]
Property and Equipment	5. Property and Equipment The Company’s property and equipment consisted of the following as of: June 30, 2024 December 31, 2023 (in thousands) Building $ 1,770 $ 1,770 Land 1,283 1,283 Equipment 9,470 2,683 Leasehold improvements 3,490 179 Other 1 319 330 Property and equipment 16,332 6,245 Less accumulated depreciation ( 1,585 ) ( 669 ) Property and equipment, net $ 14,747 $ 5,576 1. Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. On July 15, 2024 and August 2, 2024, the Company purchased a building located in Houston, Texas, for $ 4.7 million and a building in Chicago, Illinois, for $ 5.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment.

Note 6 - Goodwill and Other Int

Note 6 - Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	6. Goodwill and Other Intangible Assets Goodwill The carrying amount of goodwill as of both June 30, 2024 and December 31, 2023 was $ 24.1 million and has been recorded in connection with the Company’s Merger of Viewpoint in February 2023. The Company tests goodwill and indefinite-lived intangible assets for impairment during the fourth quarter of each year, or more frequently should circumstances change or events occur that would more likely than not reduce the fair value of its assets. No testing was deemed necessary during the three and six months ended June 30, 2024. The following table summarizes the components of the Company’s other intangible assets (in thousands): June 30, 2024 Cost Accumulated Amortization Net Carrying Value Indefinite-lived intangible assets In-process research and development $ 50,000 $ - $ 50,000 Total $ 50,000 $ - $ 50,000 December 31, 2023 Cost Accumulated Amortization Net Carrying Value Indefinite-lived intangible assets In-process research and development $ 50,000 $ - $ 50,000 Total $ 50,000 $ - $ 50,000 The Company’s IPR&D assets represent the estimated fair value of Viewpoint’s pipeline of radiotherapy product candidates acquired in February 2023. The estimated fair value of the IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for Viewpoint’s pipeline of radiotherapy program candidates were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the Merger date and the time and resources needed to complete development.

Note 7 - Held-to-Maturity Inves

Note 7 - Held-to-Maturity Investments	6 Months Ended
	Jun. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Held-to-Maturity Investments	7. Held-to-Maturity Investments The following table summarizes the carrying values and fair values of the Company’s financial instruments (in thousands): June 30, 2024 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. Treasury Bills $ 40,865 $ - $ ( 11 ) $ 40,854 The Company has investments in U.S. Treasury Bills, some of which mature over a period greater than 90 days and are classified as short-term investments. The U.S. Treasury Bills are carried at amortized cost and classified as held-to-maturity as the Company has the intent and the ability to hold them until they mature. The carrying value of the U.S. Treasury Bills are adjusted for accretion of discounts over the remaining life of the investment. Income related to the U.S. Treasury Bills is recognized in interest income in the Company’s condensed consolidated statement of operations. Based on its analysis of the held-to-maturity securities, the Company determined the gross unrealized losses were primarily due to changes in interest rates and not due to credit risks. As such, the Company did no t record a credit allowance as of June 30, 2024. As of December 31, 2023 , the Company had no held-to-maturity investments, and no held-to-maturity investments were presented in cash and cash equivalents on its condensed consolidated balance sheet.

Note 8 - Fair Value Measurement

Note 8 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	8. Fair Value Measurements Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 - Observable inputs such as quoted prices in active markets; Level 2 - Inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-driven valuations in which all significant inputs are observable or can be derived principally from, or corroborated with, observable market data; and Level 3 - Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Included in the Company’s cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands): June 30, 2024 Estimated Fair Value Money market fund $ 249,663 There were no Level 2 or Level 3 financial instruments measured at fair value on a recurring basis at June 30, 2024 , and the Company did no t have any financial instruments measured at fair value on a recurring basis at December 31, 2023. For information related to our short-term investments, see Note 7, Held-to-Maturity Investments .

Note 9 - Share-Based Compensati

Note 9 - Share-Based Compensation	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	9. Share-Based Compensation On May 31, 2024, the Company held its 2024 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Company’s stockholders approved the Company’s Third Amended and Restated 2020 Equity Incentive Plan (the Amended and Restated Plan) which, among other things, (a) increased the aggregate number of shares of Common Stock authorized for issuance under the Amended and Restated Plan by 4,870,092 for a total of 12,500,000 shares of Common Stock, and (b) adjusted the “evergreen” provision included therein, such that the number of shares of Common Stock available for the grant of awards under the Amended and Restated Plan will automatically increase on January 1 of each year in an amount equal to 5 % of the number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year (subject to adjustment in the event of stock splits and other similar events); provided, however, that the Company’s Board of Directors may act prior to January 1 of a given year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock. The following table presents the share-based compensation expense recognized for all share-based compensation arrangements (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Research and development $ 259 $ 429 $ 522 $ 584 General and administrative 328 621 687 1,448 Total share-based compensation $ 587 $ 1,050 $ 1,209 $ 2,032

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies The Company has been in settlement negotiations with a representative for six stockholder plaintiff firms alleging the Company violated Delaware law in its preliminary proxy statement that was disseminated to stockholders in November 2022 for the Company’s annual meeting held in December 2022. Based on these settlement negotiations to date, the Company estimates that it will settle for no more than an aggregate of $ 0.2 million and, therefore, recorded an estimated liability of $ 0.2 million as of December 31, 2023. There was no change in the estimate as of June 30, 2024. This balance is included in accrued expenses on the unaudited condensed consolidated balance sheets.

Note 11 - Related Parties

Note 11 - Related Parties	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	11. Related Parties In connection with the Lantheus Investment Agreement entered into with Lantheus on January 8, 2024, the Company agreed to sell and issue the Lantheus Shares. The number of Lantheus Shares sold was 5,634,235 , representing 19.99 % of the outstanding shares of Common Stock as of January 8, 2024. On January 8, 2024, the Company entered into the Progenics APA with Progenics, an affiliate of Lantheus, for a purchase price of $ 8.0 million. On March 1, 2024, the Company closed on the transactions contemplated by the Progenics APA. On March 4, 2024, the Company entered into the March 2024 Investment Agreement in which the Company agreed to issue and sell 9,200,998 shares of Common Stock. Lantheus, a significant stockholder of the Company, purchased part of the shares issued to increase their ownership percentage to approximately 19.9 % in the Company following the closing of the March 2024 Investment Agreement on March 6, 2024. For additional information regarding the Lantheus Investment Agreement, the Progenics APA and the March 2024 Investment Agreement, see Note 3, Investments and Agreements .

Note 12 - Leases

Note 12 - Leases	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Leases	12. Leases The Company accounts for its leases under ASC 842, Leases. Effective April 1, 2024, the Company entered into a lease with the Board of Regents, State of Iowa, for lab and office space at the BioVentures Center. The lease terminates in March 2026. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $ 1.1 million on the balance sheet based upon the present value of the future base payments discounted at an 8 % discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. The Company acquired a lease from Progenics, an affiliate of Lantheus, for a production facility in Somerset, New Jersey effective on March 1, 2024 (see Note 3, Investments and Agreements , in this Form 10-Q). The lease terminates on November 29, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $ 0.3 million on the balance sheet based upon the present value of the future base payments discounted at an 8 % discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. On July 1, 2023, the Company entered into a lease with Unico Properties LLC for office space in Seattle, Washington that terminates in October 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $ 0.8 million on the balance sheet based upon the present value of the future base payments discounted at an 8 % discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. The weighted average remaining term and discount rate for the Company’s operating leases as of June 30, 2024 was 3.2 years and 8 %, respectively. The Company’s operating lease expense was $ 0.2 million and $ 0.3 million for the three and six months ended June 30, 2024 , respectively, and there was no operating lease expense for the three and six months ended June 30, 2023. The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Company’s operating leases as of June 30, 2024 (in thousands): Year Ending December 31, 2024 (remaining six months) $ 408 2025 949 2026 482 2027 320 2028 283 Total 2,442 Less: imputed interest ( 272 ) Total lease liability 2,170 Less current portion ( 720 ) Non-current lease liability $ 1,450 Asset Retirement Obligation The Company had an asset retirement obligation (ARO) associated with the facility it leased in Richland, Washington. This lease is included in the GT Medical APA and was assigned to GT Medical upon the GT Medical Closing, which occurred on April 12, 2024. As such, this liability is no longer reported as an ARO in the Company’s condensed consolidated financial statements as of June 30, 2024 and December 31, 2023. However, the Company maintains the estimated liability in its condensed consolidated financial statements related to hazardous waste removal. The estimated liability at each of June 30, 2024 and December 31, 2023 was $ 0.5 million and is included within the accounts payable and accrued expenses in the condensed consolidated balance sheets.

Note 13 - Notes Payable

Note 13 - Notes Payable	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Notes Payable	13. Notes Payable The Company assumed two notes payable effective upon the closing of the Merger with Viewpoint on February 3, 2023. On July 19, 2019, Viewpoint entered in a promissory note agreement with the Iowa Economic Development Authority (IEDA) for $ 0.1 million at 3 % interest rate to be paid over 36 monthly payments beginning on the first day of the first month following Viewpoint closing on a $ 1.0 million equity fundraising round. Final payment was paid in September 2023. The loan was granted as a form of financial assistance to Viewpoint from IEDA. On December 29, 2022, Viewpoint obtained a promissory note in the amount of $ 1.7 million for the purpose of purchasing land and a building in Coralville, Iowa. The note bears interest at 6.15 % per annum and is collateralized by the property. The note requires monthly principal and interest payments, and a balloon payment of approximately $ 1.5 million is due on December 29, 2027. The following table presents the current and long-term portions of the note payable (in thousands): June 30, December 31, 2024 2023 Note payable $ 1,705 $ 1,725 Less: current portion ( 54 ) ( 49 ) Note payable, long-term portion $ 1,651 $ 1,676 The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Company’s note payable as of June 30, 2024 (in thousands): Years ending December 31: 2024 (remaining six months) $ 29 2025 52 2026 55 2027 1,569 Total $ 1,705

Note 14 - Merger

Note 14 - Merger	6 Months Ended
	Jun. 30, 2024
Business Combinations [Abstract]
Merger	14. Merger On February 3, 2023, the Company acquired 100 % of the issued and outstanding equity and voting shares of Viewpoint Molecular Targeting, Inc. in exchange for 13,654,507 shares of Common Stock with a fair value of $ 54.6 million based on the closing market price of $ 4.00 per share on the acquisition date. At the closing of the Merger, the Company forgave the note receivable entered into in November 2022 and the associated accrued interest with Viewpoint that was included in the note receivable. The total amount forgiven was $ 6.2 million, representing the $ 6.0 million loan and $ 0.2 million accrued interest. The Company also assumed all of Viewpoint’s outstanding stock options and warrants as of the Merger date. Viewpoint is developing the next generation of TAT for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. By leveraging its proprietary TAT platform, Viewpoint aims to develop alpha-emitting radiopharmaceuticals that can be attached to targeting peptides to deliver the radioactive payload directly to difficult to treat tumors. The Merger was completed to provide the Company with a new isotope in a larger market. The Company accounted for the transaction as a business combination in accordance ASC 805, Business Combinations . The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed with the assistance of an independent valuation firm. The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price): Fair value of consideration transferred Perspective Therapeutics common stock issued ( 13,654,507 x $ 4.00 ) $ 54,618 Assumption of Viewpoint stock options and warrants at fair value 7,836 Note receivable and interest from Viewpoint forgiven 6,171 Total fair value of consideration transferred $ 68,625 Recognized amounts of identifiable net assets acquired Assets acquired Cash and cash equivalents $ 2,699 Grants receivable 95 Prepaid expenses 396 Property and equipment 5,050 Right of use asset 10 Intangible assets, in-process research and development 50,000 Other assets 316 Total assets acquired 58,566 Liabilities assumed Accounts payable and accrued expenses 2,968 Lease liability 10 Accrued payroll and related taxes 1,642 Accrued vacation 333 Notes payable 1,807 Deferred tax liability 7,243 Total liabilities assumed 14,003 Net assets acquired, excluding goodwill 44,563 Total purchase price consideration 68,625 Goodwill $ 24,062 Goodwill is calculated as the difference between the acquisition date fair value of the consideration and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized and is not currently assumed to be deductible for tax purposes. The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise from the acquisition of Viewpoint. Upon completion of the Merger, Viewpoint became a wholly owned subsidiary of the Company and its results of operations have been included in the Company’s condensed consolidated financial statements. Since the closing date, Viewpoint’s results of operations have been reported in the Company’s condensed consolidated financial statements and include grant revenue of approximately $ 0.5 million and $ 0.6 million, respectively, and operating loss of $ 13.6 million and $ 7.3 million, respectively, for the three months ended June 30, 2024 and 2023, and grant revenue of approximately $ 0.9 million and $ 0.8 million, respectively, and operating loss of $ 23.7 million and $ 11.1 million, respectively, for the six months ended June 30, 2024 and 2023. The pro forma financial information below represents the combined results of operations as if the acquisition had occurred on January 1, 2022, the beginning of the comparable prior year reporting period. The unaudited pro forma financial information is presented for informational purposes only and is neither indicative of the results of operations that would have occurred if the acquisition had taken place at the beginning of the period presented nor indicative of future operating results. The information below reflects certain nonrecurring pro forma adjustments that were directly related to the business combination based on available information and certain assumptions that we believe are reasonable: Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 (in thousands) Grant revenue $ 588 $ 905 Net loss ( 9,486 ) ( 16,160 )

Disclosure - Note 1 - Basis of

Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reclassifications	Reclassifications In addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows.

Note 2 - Loss Per Share (Tables

Note 2 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares	Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands): June 30, 2024 June 30, 2023 Common stock warrants 416 603 Common stock options 6,934 4,487 Total potential dilutive securities 7,350 5,090

Note 4 - Discontinued Operati_2

Note 4 - Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations	In accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations , the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified. June 30, 2024 December 31, 2023 (in thousands) Assets held for sale of discontinued operations, current Inventory $ - $ 3,148 Prepaid expenses and other current assets - 169 Property and equipment, net - 1,263 Right-of-use asset, net - 676 Other assets, net - 45 Total current assets held for sale of discontinued operations $ - $ 5,301 Liabilities held for sale of discontinued operations, current Lease liability $ - $ 677 Asset retirement obligation - 225 Loss recognized on classification as held for sale - 4,170 Total current liabilities of discontinued operations $ - $ 5,072 The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Sales, net $ 205 $ 1,500 $ 2,178 $ 3,330 Cost of sales 162 1,840 1,564 3,416 Gross profit 43 ( 340 ) 614 ( 86 ) Operating expenses: Research and development 21 283 69 831 Sales and marketing 138 911 941 1,723 General and administrative 313 86 494 446 Total operating expenses 472 1,280 1,504 3,000 Total loss from discontinued operations $ ( 429 ) $ ( 1,620 ) $ ( 890 ) $ ( 3,086 ) Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands): Six Months Ended June 30, 2024 2023 Depreciation $ - $ 111 Amortization - 18 Write-off of inventory associated with discontinued product - 298 Share-based compensation 166 535 Additions to property and equipment - 186

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	The Company’s property and equipment consisted of the following as of: June 30, 2024 December 31, 2023 (in thousands) Building $ 1,770 $ 1,770 Land 1,283 1,283 Equipment 9,470 2,683 Leasehold improvements 3,490 179 Other 1 319 330 Property and equipment 16,332 6,245 Less accumulated depreciation ( 1,585 ) ( 669 ) Property and equipment, net $ 14,747 $ 5,576 1. Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized.

Note 6 - Goodwill and Other I_2

Note 6 - Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Components of Other Intangible Assets	The following table summarizes the components of the Company’s other intangible assets (in thousands): June 30, 2024 Cost Accumulated Amortization Net Carrying Value Indefinite-lived intangible assets In-process research and development $ 50,000 $ - $ 50,000 Total $ 50,000 $ - $ 50,000 December 31, 2023 Cost Accumulated Amortization Net Carrying Value Indefinite-lived intangible assets In-process research and development $ 50,000 $ - $ 50,000 Total $ 50,000 $ - $ 50,000

Note 7 - Held-to-Maturity Inv_2

Note 7 - Held-to-Maturity Investments (Tables)	6 Months Ended
	Jun. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Summary of Carrying Values and Fair Values of Financial Instruments	The following table summarizes the carrying values and fair values of the Company’s financial instruments (in thousands): June 30, 2024 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. Treasury Bills $ 40,865 $ - $ ( 11 ) $ 40,854

Note 8 - Fair Value Measureme_2

Note 8 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis	Company’s cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands): June 30, 2024 Estimated Fair Value Money market fund $ 249,663

Note 9 - Share-Based Compensa_2

Note 9 - Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements	The following table presents the share-based compensation expense recognized for all share-based compensation arrangements (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Research and development $ 259 $ 429 $ 522 $ 584 General and administrative 328 621 687 1,448 Total share-based compensation $ 587 $ 1,050 $ 1,209 $ 2,032

Note 12 - Leases (Tables)

Note 12 - Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Summary of Future Operating Lease Payments and Lease Liability	The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Company’s operating leases as of June 30, 2024 (in thousands): Year Ending December 31, 2024 (remaining six months) $ 408 2025 949 2026 482 2027 320 2028 283 Total 2,442 Less: imputed interest ( 272 ) Total lease liability 2,170 Less current portion ( 720 ) Non-current lease liability $ 1,450

Note 13 - Notes Payable (Tables

Note 13 - Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Summary of Note Payable	The following table presents the current and long-term portions of the note payable (in thousands): June 30, December 31, 2024 2023 Note payable $ 1,705 $ 1,725 Less: current portion ( 54 ) ( 49 ) Note payable, long-term portion $ 1,651 $ 1,676
Summary of Maturity of Note Payable	The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Company’s note payable as of June 30, 2024 (in thousands): Years ending December 31: 2024 (remaining six months) $ 29 2025 52 2026 55 2027 1,569 Total $ 1,705

Note 14 - Merger (Tables)

Note 14 - Merger (Tables)	6 Months Ended
	Jun. 30, 2024
Business Combinations [Abstract]
Summary of Estimated Purchase Consideration	The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price): Fair value of consideration transferred Perspective Therapeutics common stock issued ( 13,654,507 x $ 4.00 ) $ 54,618 Assumption of Viewpoint stock options and warrants at fair value 7,836 Note receivable and interest from Viewpoint forgiven 6,171 Total fair value of consideration transferred $ 68,625
Summary of Preliminary Purchase Price Allocation	Recognized amounts of identifiable net assets acquired Assets acquired Cash and cash equivalents $ 2,699 Grants receivable 95 Prepaid expenses 396 Property and equipment 5,050 Right of use asset 10 Intangible assets, in-process research and development 50,000 Other assets 316 Total assets acquired 58,566 Liabilities assumed Accounts payable and accrued expenses 2,968 Lease liability 10 Accrued payroll and related taxes 1,642 Accrued vacation 333 Notes payable 1,807 Deferred tax liability 7,243 Total liabilities assumed 14,003 Net assets acquired, excluding goodwill 44,563 Total purchase price consideration 68,625 Goodwill $ 24,062
Summary of Pro Forma Computation of Earnings Per Share	The information below reflects certain nonrecurring pro forma adjustments that were directly related to the business combination based on available information and certain assumptions that we believe are reasonable: Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 (in thousands) Grant revenue $ 588 $ 905 Net loss ( 9,486 ) ( 16,160 )

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 14, 2024	Apr. 12, 2024 $ / shares shares	Apr. 11, 2024 USD ($) $ / shares shares	Feb. 03, 2023 $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, par value | $ / shares					$ 0.001	$ 0.001		$ 0.001
Reverse stock split, ratio	0.1
Cash, cash equivalents and short-term investments | $						$ 292,900		$ 292,900
Accumulated deficit | $					$ (152,440)	(176,428)		(176,428)
Loss on equity method investment | $						$ 4	$ 0	$ 6	$ 0
Forecast [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Effective income tax rate										0%
GT Medical Technologies, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares | shares		279,516
Common stock, par value | $ / shares		$ 0.0001
Percentage of issued and outstanding capital stock		0.50%
Oppenheimer & Co [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares | shares			3,535,246		123,882
Stock purchase price per share | $ / shares			$ 14		$ 3.03
Proceeds from issuance of common stock | $			$ 49,500		$ 400
Viewpoint Molecular Targeting, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock issued pursuant to merger, Shares | shares				13,654,507
Percentage of fully-diluted outstanding capital stock				49%
Common stock, par value | $ / shares				$ 0.001

Note 2 - Loss Per Share - Sched

Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	7,350	5,090
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	416	603
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	6,934	4,487

Note 2 - Loss Per Share (Detail

Note 2 - Loss Per Share (Details Textual) - Viewpoint Molecular Targeting, Inc. [Member]	Feb. 03, 2023 $ / shares shares
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Warrants to purchase shares of common stock | shares	338,709
Warrant exercise price per share	$ 2.7
Options to purchase shares of common stock | shares	2,426,342
Minimum [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Options exercise price per share	$ 1.3
Maximum [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Options exercise price per share	$ 3

Note 3 - Investments and Agre_2

Note 3 - Investments and Agreements (Details Textual) - USD ($)						1 Months Ended
	May 24, 2024	Apr. 11, 2024	Mar. 04, 2024	Jan. 17, 2024	Jan. 08, 2024	Dec. 31, 2023	Jun. 30, 2024	Mar. 31, 2024	Dec. 14, 2023	Nov. 17, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, par value						$ 0.001	$ 0.001
Maximum amount of securities offer and sale									$ 200,000,000
January 2024 Pre-funded Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase shares of common stock				3,008,694
Warrant exercise price per share				$ 3.69
Percentage of ownership considered for warrant exercise				4.99%
Maximum increase or decrease in ownership percentage				19.99%
March 2024 Private Placement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares			9,200,998
Stock purchase price per share			$ 9.5
Proceeds from issuance of common stock			$ 87,400,000
Placement agents cash fee, percentage			5.85%
Lantheus Investment Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares					5,634,235
Investment agreement, contingent amount of gross proceeds raised					$ 50,000,000
Percent of outstanding shares					19.99%
Asset purchase price in cash					$ 8,000,000
Lantheus Investment Agreement | Option Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of outstanding shares								19.90%
One-time payment received for rights granted					28,000,000
Repayment provisions					$ 0
Public Offering [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares				13,207,521
Sale of stock, price per share				$ 3.7
Shares and warrants, price difference per share				$ 0.01
Gross proceeds from public offering				$ 69,000,000
Over-Allotment Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares				2,432,432
Oppenheimer & Co [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares		3,535,246				123,882
Stock purchase price per share		$ 14				$ 3.03
Proceeds from issuance of common stock		$ 49,500,000				$ 400,000
Maximum amount of securities offer and sale										$ 50,000,000
BofA Securities, Inc [Member] | Underwriting Agreement [Member] | May 2024 Pre-funded Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase shares of common stock	146,425
Warrant exercise price per share	$ 15.09
Percentage of ownership considered for warrant exercise	4.99%
Percentage of ownership considered for warrant exercise	9.99%
Maximum increase or decrease in ownership percentage	19.99%
BofA Securities, Inc [Member] | Registered Offering [Member] | Underwriting Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares	5,151,588
Sale of stock, price per share	$ 15.1
Shares and warrants, price difference per share	$ 0.01
Gross proceeds from public offering	$ 80,000,000

Note 4 - Discontinued Operati_3

Note 4 - Discontinued Operations (Details Textual) - USD ($)		3 Months Ended		6 Months Ended
	Apr. 12, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Common stock, par value		$ 0.001		$ 0.001		$ 0.001
Discontinued operations, Provision (benefit) for income taxes		$ 0	$ 0	$ 0	$ 0
GT Medical Technologies, Inc. [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock issued during period, shares	279,516
Common stock, par value	$ 0.0001
Percentage of issued and outstanding capital stock	0.50%
Royalty agreement percentage of net sales receivable	0.50%
GT Medical Technologies, Inc. [Member] | Net Sales of $10 Million or Less [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalty agreement percentage of net sales receivable	3%
GT Medical Technologies, Inc. [Member] | Net Sales Between $10 and 15 Million [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalty agreement percentage of net sales receivable	4%
GT Medical Technologies, Inc. [Member] | Net Sales Greater Than $15 Million [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalty agreement percentage of net sales receivable	5%
GT Medical Technologies, Inc. [Member] | GT Medical Stock [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Estimated fair value	$ 200,000

Note 4 - Discontinued Operati_4

Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Assets held for sale of discontinued operations, current
Total current assets held for sale of discontinued operations	$ 0		$ 0		$ 5,301
Liabilities held for sale of discontinued operations, current
Total current liabilities of discontinued operations	0		0		5,072
Depreciation			916	$ 425
Amortization			12	20
Write-off of inventory associated with discontinued product			0	298
Share-based compensation			1,375	2,567
Additions to property and equipment			10,087	756
Discontinued Operations, Disposed of by Sale [Member] | Cesium-131 Business [Member]
Assets held for sale of discontinued operations, current
Inventory	0		0		3,148
Prepaid expenses and other current assets	0		0		169
Property and equipment, net	0		0		1,263
Right-of-use asset, net	0		0		676
Other assets, net	0		0		45
Total current assets held for sale of discontinued operations	0		0		5,301
Liabilities held for sale of discontinued operations, current
Lease liability	0		0		677
Asset retirement obligation	0		0		225
Loss recognized on classification as held for sale	0		0		4,170
Total current liabilities of discontinued operations	0		0		$ 5,072
Sales, net	205	$ 1,500	2,178	3,330
Cost of sales	162	1,840	1,564	3,416
Gross profit	43	(340)	614	(86)
Research and development	21	283	69	831
Sales and marketing	138	911	941	1,723
General and administrative	313	86	494	446
Total operating expenses	472	1,280	1,504	3,000
Total loss from discontinued operations	$ (429)	$ (1,620)	(890)	(3,086)
Depreciation			0	111
Amortization			0	18
Write-off of inventory associated with discontinued product			0	298
Share-based compensation			166	535
Additions to property and equipment			$ 0	$ 186

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)			6 Months Ended		12 Months Ended
	Aug. 02, 2024	Jul. 15, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Depreciation expense			$ 916,000	$ 425,000
Houston Texas [Member] | Subsequent Event [Member]
Property, Plant and Equipment [Line Items]
Payments to purchase buildings		$ 4,700,000
Chicago Illinois [Member] | Subsequent Event [Member]
Property, Plant and Equipment [Line Items]
Payments to purchase buildings	$ 5,000,000
Other [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense			$ 0		$ 0

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 16,332	$ 6,245
Less accumulated depreciation		(1,585)	(669)
Property and equipment, net		14,747	5,576
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		1,770	1,770
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		1,283	1,283
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		9,470	2,683
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		3,490	179
Other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	[1]	$ 319	$ 330
[1] Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. On July 15, 2024 and August 2, 2024, the Company purchased a building located in Houston, Texas, for $ 4.7 million and a building in Chicago, Illinois, for $ 5.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment.

Note 6 - Goodwill and Other I_3

Note 6 - Goodwill and Other Intangible Assets (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 24,062	$ 24,062

Note 6 - Goodwill and Other I_4

Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Indefinite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 50,000	$ 50,000
Accumulated Amortization	0	0
In Process Research and Development [Member]
Indefinite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	50,000	50,000
Accumulated Amortization	$ 0	$ 0

Note 7 - Held-to-Maturity Inv_3

Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details) - U.S. Treasury Bills [Member] $ in Thousands	Jun. 30, 2024 USD ($)
Schedule of Held-to-Maturity Securities [Line Items]
HTM, amortized cost, Total	$ 40,865
HTM, Gross Unrealized Gains	0
HTM, Gross Unrealized Losses	(11)
HTM, Estimated Fair Value	$ 40,854

Note 7 - Held-to-Maturity Inv_4

Note 7 - Held-to-Maturity Investments (Details Textual) - U.S. Treasury Bills [Member] - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Held-to-Maturity Securities [Line Items]
Held-to-maturity, allowance for credit loss	$ 0
Held-to-maturity investments		$ 0
Cash and Cash Equivalents [Member]
Schedule of Held-to-Maturity Securities [Line Items]
Held-to-maturity investments		$ 0

Note 8 - Fair Value Measureme_3

Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 249,663

Note 8 - Fair Value Measureme_4

Note 8 - Fair Value Measurements (Details Textual) - Fair Value, Recurring [Member] - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instruments measured at fair value		$ 0
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instruments measured at fair value	$ 0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instruments measured at fair value	$ 0

Note 9 - Share-Based Compensa_3

Note 9 - Share-Based Compensation (Details Textual) - Amended 2020 Incentive Plan [Member]	May 31, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	4,870,092
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	12,500,000
Percentage of increase in common stock capital shares for future issuance	5%

Note 9 - Share-Based Compensa_4

Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 587	$ 1,050	$ 1,209	$ 2,032
Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	259	429	522	584
General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 328	$ 621	$ 687	$ 1,448

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual)	6 Months Ended
	Jun. 30, 2024 USD ($) Plaintiff	Dec. 31, 2023 USD ($)
Loss Contingencies [Line Items]
Number of plaintiff | Plaintiff	6
Aggregate maximum estimate settlement amount		$ 200,000
Stockholder Plaintiff Settlements
Loss Contingencies [Line Items]
Estimated liability	$ 200,000	$ 200,000

Note 11 - Related Parties (Deta

Note 11 - Related Parties (Detailed Textual) - USD ($) $ in Millions	Mar. 04, 2024	Jan. 08, 2024	Mar. 06, 2024
Lantheus Investment Agreement [Member]
Related Party Transaction [Line Items]
Shares issued and sell		5,634,235
Percent of outstanding shares		19.99%
Purchase price		$ 8
Lantheus Alpha Therapy, LLC [Member] | Lantheus Investment Agreement [Member]
Related Party Transaction [Line Items]
Shares issued and sell	9,200,998	5,634,235
Percent of outstanding shares		19.99%	19.90%
Progenics APA [Member]
Related Party Transaction [Line Items]
Purchase price		$ 8

Note 12 - Leases (Details Textu

Note 12 - Leases (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Apr. 01, 2024	Mar. 01, 2024	Dec. 31, 2023	Jul. 01, 2023
Lessee, Lease, Description [Line Items]
Lease liability	$ 2,170,000		$ 2,170,000
Right of use asset	$ 2,019,000		$ 2,019,000				$ 747,000
Operating lease, weighted average remaining term	3 years 2 months 12 days		3 years 2 months 12 days
Operating lease, weighted average discount rate	8%		8%
Operating lease, expense	$ 200,000	$ 0	$ 300	$ 0
Estimated hazardous waste removal liability	$ 500,000		$ 500,000				$ 500,000
Office Space With Unico Properties [Member]
Lessee, Lease, Description [Line Items]
Lease liability								$ 800,000
Right of use asset								$ 800,000
Lessee, operating lease, discount rate								8%
Lease with Board of Regents [Member]
Lessee, Lease, Description [Line Items]
Lease liability					$ 1,100,000
Right of use asset					$ 1,100,000
Lessee, operating lease, discount rate					8%
Progenics [Member]
Lessee, Lease, Description [Line Items]
Lease liability						$ 300,000
Right of use asset						$ 300,000
Lessee, operating lease, discount rate						8%

Note 12 - Leases - Summary of F

Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Leases [Abstract]
2024 (remaining six months)	$ 408
2025	949
2026	482
2027	320
2028	283
Total	2,442
Less: imputed interest	(272)
Total lease liability, Total	2,170
Less current portion	(720)	$ (46)
Non-current lease liability	$ 1,450	$ 780

Note 13 - Notes Payable (Detail

Note 13 - Notes Payable (Details Textual) $ in Thousands	Jul. 19, 2019 USD ($) MonthlyPayments	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 29, 2022 USD ($)
Debt Instrument [Line Items]
Notes payable, current		$ 54	$ 49
Promissory Note [Member]
Debt Instrument [Line Items]
Notes payable, current		$ 54	$ 49
Viewpoint Molecular Targeting, Inc. [Member] | Promissory Note [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 100
Debt instrument, interest rate	3%
Debt instrument, number of monthly payments | MonthlyPayments	36
Amount raised through selling of equity	$ 1,000
Viewpoint Molecular Targeting, Inc. [Member] | Promissory Note for Purchasing Land and Building [Member]
Debt Instrument [Line Items]
Debt instrument, face amount				$ 1,700
Debt instrument, interest rate				6.15%
Debt instrument balloon payment				$ 1,500

Note 13 - Notes Payable - Summa

Note 13 - Notes Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Less: current portion	$ (54)	$ (49)
Note payable, long-term portion	1,651	1,676
Promissory Note [Member]
Debt Instrument [Line Items]
Note payable	1,705	1,725
Less: current portion	(54)	(49)
Note payable, long-term portion	$ 1,651	$ 1,676

Note 13 - Notes Payable - Sum_2

Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Maturities of Long-Term Debt [Abstract]
2024 (remaining six months)	$ 29
2025	52
2026	55
2027	1,569
Total	$ 1,705

Note 14 - Merger (Details Textu

Note 14 - Merger (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Feb. 03, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Nov. 22, 2022
Business Acquisition [Line Items]
Grant revenue		$ 526	$ 588	$ 851	$ 821
Operating loss		(14,263)	(9,754)	(27,268)	(19,515)
Viewpoint Molecular Targeting, Inc. [Member]
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired	100%
Business acquisition, number of common shares exchanged	13,654,507
Business combination, fair value of common stock	$ 54,618
Business acquisition, closing market price	$ 4
Note receivable, forgiven amount	$ 6,200
Grant revenue		500	600	900	800
Operating loss		$ (13,600)	$ (7,300)	$ (23,700)	$ (11,100)
Viewpoint Molecular Targeting, Inc. [Member] | Isoray Note [Member]
Business Acquisition [Line Items]
Note receivable, forgiven amount, loan						$ 6,000
Accrued interest						$ 200

Note 14 - Merger - Summary of E

Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) - Viewpoint Molecular Targeting, Inc. [Member] $ in Thousands	Feb. 03, 2023 USD ($)
Business Acquisition [Line Items]
Perspective Therapeutics common stock issued (13,654,507 x $4.00)	$ 54,618
Assumption of Viewpoint stock options and warrants at fair value	7,836
Note receivable and interest from Viewpoint forgiven	6,171
Total fair value of consideration transferred	$ 68,625

Note 14 - Merger - Summary of_2

Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals) - Viewpoint Molecular Targeting, Inc. [Member]	Feb. 03, 2023 $ / shares shares
Business Acquisition [Line Items]
Business acquisition, shares (in shares) | shares	13,654,507
Business acquisition, price per share (in dollars per share) | $ / shares	$ 4

Note 14 - Merger - Summary of P

Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details) - USD ($) $ in Thousands	Feb. 03, 2023	Jun. 30, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill		$ 24,062	$ 24,062
Viewpoint Molecular Targeting, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	$ 2,699
Grants receivable	95
Prepaid expenses	396
Property and equipment	5,050
Right of use asset	10
Intangible assets, in-process research and development	50,000
Other assets	316
Total assets acquired	58,566
Accounts payable and accrued expenses	2,968
Lease liability	10
Accrued payroll and related taxes	1,642
Accrued vacation	333
Notes payable	1,807
Deferred tax liability	7,243
Total liabilities assumed	14,003
Net assets acquired, excluding goodwill	44,563
Total purchase price consideration	68,625
Goodwill	$ 24,062

Note 14 - Merger - Summary of_3

Note 14 - Merger - Summary of Pro Forma Computation of Earnings Per Share (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Business Combinations [Abstract]
Grant revenue	$ 588	$ 905
Net loss	$ (9,486)	$ (16,160)